Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
暂无分享,去创建一个
P. Sonneveld | M. Kersten | G. Mulligan | D. Hose | H. Goldschmidt | A. Jauch | P. Sonneveld | E. Vellenga | B. van der Holt | J. Peeters | H. Beverloo | A. Buijs | H. Lokhorst | M. Stevens-Kroef | M. van Duin | U. Bertsch | A. Broyl | S. Zweegman | A. Broyl | D. Hose | H. Lokhorst | Y. de Knegt | J. Peeters | A. Jauch | U. Bertsch | A. Buijs | M. Stevens-Kroef | H. B. Beverloo | E. Vellenga | S. Zweegman | M.-J. Kersten | B. van der Holt | L. el Jarari | G. Mulligan | H. Goldschmidt | M. van Duin | Laila el Jarari | Yvonne de Knegt
[1] V. Pantesco,et al. Gene expression of anti‐ and pro‐apoptotic proteins in malignant and normal plasma cells , 2009, British journal of haematology.
[2] Axel Benner,et al. Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. , 2008, Blood.
[3] M. Kersten,et al. First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM) , 2008 .
[4] H. Kazazian,et al. Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII , 2008 .
[5] Laurence Lodé,et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Ahmet Dogan,et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. , 2008, Blood.
[7] F. Zhan,et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. , 2008, Blood.
[8] G. Donofrio,et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. , 2007, Cancer research.
[9] L. Bruhn,et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.
[10] L. Staudt,et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.
[11] Rafael Fonseca,et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.
[12] P. Raynaud,et al. Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis1 , 2007, The Journal of Immunology.
[13] Anthony Boral,et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.
[14] T. Rème,et al. CD200 is a new prognostic factor in multiple myeloma. , 2006, Blood.
[15] Yongsheng Huang,et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.
[16] John Crowley,et al. The molecular classification of multiple myeloma. , 2006, Blood.
[17] G. Ahmann,et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations , 2006, Leukemia.
[18] D. Hose,et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics , 2005, Genes, chromosomes & cancer.
[19] G. Ahmann,et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. , 2005, Blood.
[20] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Bart Barlogie,et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.
[22] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .
[23] Lin-Feng Chen,et al. NF-κB Is Essential for Induction of CYLD, the Negative Regulator of NF-κB , 2004, Journal of Biological Chemistry.
[24] F. Zhan,et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.
[25] J. Soulier,et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases , 2003, Genes, chromosomes & cancer.
[26] R. Fonseca,et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. , 2003, Blood.
[27] R. Bataille,et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. , 2003, Blood.
[28] Tony Reiman,et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.
[29] J. Baars,et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. , 2002, Blood.
[30] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[31] C. Bastard,et al. Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.
[32] Christian A. Rees,et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[33] T. Hunter,et al. Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling , 1995, Cell.
[34] Hong Sun,et al. The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. , 1994, Trends in biochemical sciences.
[35] H. Clevers,et al. Identification of primary MAFB target genes in multiple myeloma. , 2009, Experimental hematology.
[36] S. Bicciato,et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. , 2007, Haematologica.
[37] J. V. van Dongen,et al. Two dual-color split signal fluorescence in situ hybridization assays to detect t(5;14) involving HOX11L2 or CSX in T-cell acute lymphoblastic leukemia. , 2004, Haematologica.
[38] Lin-Feng Chen,et al. NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. , 2004, The Journal of biological chemistry.
[39] T. Otsuki,et al. Upregulated production of IL-6, but not IL-10, by interferon-alpha induces SOCS3 expression and attenuates STAT1 phosphorylation in myeloma cells. , 2004, The hematology journal : the official journal of the European Haematology Association.
[40] G. Ahmann,et al. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. , 1999, Leukemia & lymphoma.
[41] J. Turkson,et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.
[42] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[43] B. Zhivotovsky,et al. Interferon (cid:1) -induced Apoptosis in Tumor Cells Is Mediated through the Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Signaling Pathway* , 2022 .